Tevogen Bio Holdings Inc. (NASDAQ:TVGN) is preparing for a significant change with a reverse stock split scheduled for March 6, 2026. This biotechnology company, which focuses on developing innovative therapies, will exchange 1 share for every 50 shares. The decision, approved by the Board of Directors, aims to address the company's current stock price challenges. The reverse stock split is a strategic move to meet the Nasdaq Global Market's $1.00 minimum bid price requirement. As highlighted by the company's recent announcement, the stockholder approval on February 19, 2026, granted the Board the discretion to finalize the split ratio.
This adjustment is crucial for maintaining TVGN's listing status on the Nasdaq exchange. Currently, TVGN's stock is priced at $0.15, reflecting a 16.70% decrease with a change of $0.03. The stock has fluctuated between $0.14 and $0.18 yesterday, with a 52-week high of $1.51 and a low of $0.14. The reverse split will adjust the stock price, potentially bringing it above the $1.00 threshold.
TVGN's market capitalization is approximately $31.3 million, with a trading volume of 2,180,275 shares. After the reverse split, the stock will trade on a split-adjusted basis under the same symbol, "TVGN," but with a new CUSIP number, 88165K 200. This change is expected to enhance the stock's appeal to investors by aligning with Nasdaq's listing requirements.
